Bausch + Lomb Co. (NYSE:BLCO) Receives $20.00 Average Price Target from Analysts

Bausch + Lomb Co. (NYSE:BLCO - Get Free Report) has received an average recommendation of "Hold" from the twelve research firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $20.00.

A number of analysts recently issued reports on the company. Citigroup cut Bausch + Lomb from a "buy" rating to a "neutral" rating and dropped their price objective for the stock from $24.00 to $22.00 in a report on Wednesday, December 11th. Bank of America decreased their price target on Bausch + Lomb from $18.00 to $17.00 and set an "underperform" rating on the stock in a research report on Thursday, February 20th. Wells Fargo & Company cut their price objective on shares of Bausch + Lomb from $26.00 to $24.00 and set an "overweight" rating for the company in a research report on Thursday, January 16th. HC Wainwright reaffirmed a "buy" rating and set a $23.00 target price on shares of Bausch + Lomb in a report on Tuesday, February 18th. Finally, Stifel Nicolaus lowered their target price on shares of Bausch + Lomb from $19.00 to $18.00 and set a "hold" rating on the stock in a research note on Wednesday, January 29th.

Bausch + Lomb Stock Performance

NYSE:BLCO traded up $0.35 on Friday, reaching $15.91. 408,556 shares of the company's stock were exchanged, compared to its average volume of 578,099. The firm has a market cap of $5.61 billion, a price-to-earnings ratio of -17.48, a P/E/G ratio of 0.85 and a beta of 0.49. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.60 and a quick ratio of 1.01. The stock has a fifty day simple moving average of $16.43 and a 200-day simple moving average of $18.12. Bausch + Lomb has a 52 week low of $13.16 and a 52 week high of $21.69.

Remove Ads

Bausch + Lomb (NYSE:BLCO - Get Free Report) last released its quarterly earnings data on Wednesday, February 19th. The company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.23 by $0.02. Bausch + Lomb had a negative net margin of 6.62% and a positive return on equity of 3.35%. The company had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.26 billion. During the same period last year, the firm earned $0.24 EPS. Bausch + Lomb's revenue for the quarter was up 9.1% on a year-over-year basis. As a group, sell-side analysts predict that Bausch + Lomb will post 0.74 earnings per share for the current year.

Hedge Funds Weigh In On Bausch + Lomb

Several institutional investors have recently modified their holdings of the company. Blue Trust Inc. grew its position in Bausch + Lomb by 68.3% during the fourth quarter. Blue Trust Inc. now owns 2,474 shares of the company's stock valued at $48,000 after acquiring an additional 1,004 shares during the last quarter. FNY Investment Advisers LLC purchased a new position in Bausch + Lomb in the 4th quarter worth $72,000. Commonwealth Equity Services LLC bought a new stake in Bausch + Lomb in the fourth quarter worth $181,000. Alpine Global Management LLC purchased a new stake in Bausch + Lomb during the fourth quarter valued at about $181,000. Finally, Covestor Ltd bought a new position in shares of Bausch + Lomb during the fourth quarter valued at about $188,000. 11.07% of the stock is currently owned by institutional investors.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.